On Tuesday, Qualys Inc (NASDAQ:QLYS)’s shares declined -32.77% to $37.03.
Qualys Inc (QLYS) declared the release of “Vulnerability Administration for Dummies, Second Edition,” its newly revised eBook designed to provide network security teams with a clearer understanding of vulnerability administration (VM). The eBook will provide guidance on how to implement a successful VM program, together with continuous monitoring, in an ever-evolving IT security landscape.
Qualys, Inc. provides cloud security and compliance solutions in the United States and internationally. The company offers QualysGuard cloud suite of solutions, such as Vulnerability Administration, Policy Compliance, PCI Compliance, Web Application Scanning, Malware Detection Service, Web Application Firewall, and Qualys SECURE Seal.
xG Technology Inc (NASDAQ:XGTI)’s shares dropped -29.50% to $0.380.
xG Technology Inc (XGTI) declared that it has been awarded a new patent covering improved techniques for mitigating interference in wireless transmissions. The new patent, “Hybrid ARQ system with Snapshot Feedback Mechanism for Interference Prone Wireless Networks,” outlines a method for faster and more detailed analysis of data being received, which will assist deliver smoother and more reliable communications in crowded and challenged RF (radio frequency) environments.
xG Technology, Inc. develops communications technologies for wireless networks worldwide. The company’s intellectual property is embedded in proprietary software algorithms designed to offer cognitive interference mitigation and spectrum access solutions to organizations in a various industries, counting national defense and rural broadband.
At the end of Tuesday’s trade, AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)‘s shares dipped -27.74% to $3.04.
AcelRx Pharmaceuticals Inc (ACRX) offered a regulatory update on Zalviso and stated financial results for the three months ended March 31, 2015.
Zalviso Regulatory Update
On April 21, 2015, AcelRx presented a request to the Division of Anesthesia, Analgesia, and Addiction Products (DAAAP or the Division) of the Food and Drug Administration (FDA) for a Type B meeting. This past Friday the Division notified the Company that the request for a meeting was denied and restated the Division’s view that a clinical study is required. We are consulting with our regulatory, legal and clinical advisors to determine our next steps. We will be considering all options to determine a pathway forward for Zalviso counting the possibility of dispute resolution through one of the FDA prescribed pathways in addition to conducting additional clinical or Human Factors studies.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The companys lead product candidate is Zalviso, an investigational, pre-programmed, non-invasive, handheld system that has accomplished Phase III clinical trials for the treatment of moderate-to-severe acute pain in the hospital setting.
InterCloud Systems Inc (NASDAQ:ICLD), ended its Tuesday’s trading session with -26.10% loss, and closed at $3.03.
InterCloud Systems Inc (ICLD) a single-source provider of end-to-end information technology (IT) and next-generation network solutions counting Software Defined Networking (SDN) and Network Functions Virtualization (NFV) to the telecommunications service provider (carrier) and corporate enterprise markets through cloud solutions and professional services, declared recently the launching of NFVGrid, a Network Functions Virtualization Orchestration platform.
InterCloud Systems, Inc. provides end-to-end IT and network solutions to the telecommunications service provider and corporate enterprise markets through cloud platforms and professional services in the United States and internationally. It operates through three segments: Applications and Infrastructure, Professional Services, and Cloud and Managed Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
